

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Iver Cooper on July 15, 2010, July 19, 2010, and July 20, 2010.

The application has been amended as follows:

Claim 1 (Currently Amended) A vaccine composition comprising an immunogenically active peptide ~~or a nucleic acid encoding said peptide~~ wherein the peptide consists of at the most 15 amino acids and comprises SEQ ID NO:8 or a sequence which differs from SEQ ID NO:8 by one or two amino acid substitutions.

50. (Currently Amended) The vaccine composition according to claim 1, wherein the vaccine composition further comprises antigen presenting cells comprising the peptide ~~or nucleic acid of claim 1~~.

Claims 54 and 55 have been canceled.

56. (Currently Amended) The vaccine composition according to ~~claim 54~~ claim 1, ~~wherein the vector furthermore comprises nucleic acids encoding~~ comprising a T-cell stimulatory polypeptide.

Claims 66, 71-75, and 81 have been canceled.

Claim 88, line 2, "if at all" has been deleted.

Claim 89, line 2, "nonetheless" has been deleted.

Claim 91, line 2, "if at all" has been deleted.

Claim 92, line 2, "nonetheless" has been deleted.

Withdrawn claims 29, 30, 50, and 51, and 56 and 57 are rejoined and allowed.

The following is an examiner's statement of reasons for allowance: The new claims 88 and 91 have support in original claim 37, which lists the anchor positions of HLA-A2 be to at 2, 6, and the C terminal residues (position 10 in case of SEQ ID NO: 8), and the specification on page 40, Table 1 discloses that the testing of the various peptides with HLA-A2.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MISOOK YU whose telephone number is 571-272-0839. The examiner can normally be reached on 8 A.M. to 5:30 P.M., every other Friday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry Helms can be reached on 571-272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

MISOOK YU  
Primary Examiner  
Art Unit 1642

/MISOOK YU/  
Primary Examiner, Art Unit 1642